title: HCT116 siMYCLo-2-1 Cancer reference kit-1

status: Public on Sep 06 2013

city: Columbus

first: Taewan

last: Kim

state: OH

institute: The Ohio State University

hyb_protocol: Hybridization reactions were performed according to manufacturer's instructions with 5µl of the 5-fold diluted sample preparation reaction. All hybridization reactions were incubated at 64°C for a minimum of 18 h.

scan_protocol: A high-density scan (600 fields of view) was performed.

data_processing: The analysis of raw data was performed with nSlover Analysis Software provided by NanoString Technologies. The raw data was normalized with GADPH expression.

source_name: Colorectal cancer-derived HCT116 cell line

growth_protocol: Cells were grown in 37 degree humidified incubator with 5% CO2.

extract_protocol: Total RNA samples were prepared using TRIZOL (Invitrogen) in accordance with manufacturer's instruction.

treatment_protocol: Cells were transfected with siRNA (Final concentration: 50nM for HCT116 and 100nM for PC3) by using Lipofectamine RNAiMAX from Invitrogen as the instruction of manufacturer.

value: siRNA targeting CARLo-3


title: Day 1 Low dose TiO2 Treated 2

status: Public on Nov 01 2013

type: RNA

city: Ottawa

first: Mainul

last: Husain

address: 50 Colombine Driveway

country: Canada

institute: Health Canada

description: Biological replicate 2 of low dose sample, harvested 1 day post-instillation

hyb_protocol: Each experimental cRNA sample was mixed with an equimolar amount of reference cRNA and was hybridized to Agilent mouse 4×44 oligonucleotide microarrays (Agilent Technologies Inc., Mississauga, ON, Canada) for 17 h in a hybridization chamber at 60C with a rotation speed of 10 rpm.

scan_protocol: Arrays were washed according to manufacturer’s protocols (Agilent Technologies Inc., Mississauga, ON, Canada) and scanned on an Agilent G2505B scanner.

data_processing: Data from the scanned images were extracted using Agilent Feature Extraction software version 9.5.3.1. Data were normalized using LOWESS method and the normalized data represent the log2 of the ratios (sample(Cy5)/reference(Cy3)) of the median signal intensities.

molecule: total RNA

organism: Mus musculus

source_name: Agilent Universal Mouse Reference RNA (UMRR)

label_protocol: Total RNA (250 ng) samples from individual mice (n = 6 per experimental and control group) and from universal reference total RNA (Agilent Technologies, Inc., Mississauga, ON, Canada) were used to synthesize double-stranded cDNA and cyanine labelled cRNA using Quick Amp Labeling Kit (Agilent Technologies Inc., Mississauga, ON, Canada) according to the manufacturer’s instruction. Control and nano-TiO2 treated cRNAs were labelled with Cyanine 5-CTP, and reference RNAs were labelled with Cyanine 3-CTP using a T7 RNA polymerase in vitro transcription kit (Agilent Technologies Inc., Mississauga, ON, Canada) and purified using RNeasy Mini kits (Qiagen, Mississauga, ON, Canada).

growth_protocol: Five-to-seven week old female C57BL/6 mice were purchased from Taconic (Ry, Denmark) and were acclimatized for 1-3 weeks prior to the commencement of the experiment. Mice were maintained in groups in polypropylene cages with sawdust bedding and enrichment, at 20-22°C room temperature and relative humidity of 40-60% with a 12 h light-to-dark cycle. All mice received food and water ad libitum throughout the experiment. All animal experiments were approved by the Danish “Animal Experiments Inspectorate” and performed according to their guidelines for ethical conduct and care of animals in research.

extract_protocol: Total RNA was isolated from random sections of the left lungs (n = 5-6 per group) using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purified using RNeasy Plus Mini kits (Qiagen, Mississauga, ON, Canada) according to the manufacturer’s instruction. Total RNA concentration was measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA) and RNA quality and integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Mississauga, ON, Canada) according to the manufacturer’s instruction. Samples with RNA integrity numbers of 7 and above were used to conduct microarray and qPCR experiments.

treatment_protocol: Naïve C57BL/6 mice were flushed twice with 0.6 ml of 0.9% NaCl to obtain approximately 1 ml of bronchoalveolar lavage fluid (BAL). BAL was centrifuged at 400 g for 10 min at 4°C to remove cells. The supernatant was used in the dispersant liquid. A total of 4.05 mg of nano-TiO2 was suspended in 1 ml of MilliQ water containing 0.9% NaCl and 10% v/v acellular BAL. Particle suspensions were prepared by sonicating the samples using a S-450D sonifier (Branson Ultrasonics Corp., Danbury, CT, USA) at 10% amplitude for a total of 16 minutes on ice with alternating 10 s pulses and pauses. Three different dilutions of nano-TiO2 were prepared and used in this experiment: 162 µg, 54 µg (1:3 dilution of the 162 µg) and 18 µg (1:3 dilution of the 54 µg). Control vehicle solutions were prepared without the nano-TiO2 (MilliQ water containing 90% of 0.9% NaCl and 10% acellular BAL fluid). The doses 18, 54 and 162 μg/mouse equal 1.5, 5 and 15 working days at the Danish occupational exposure level for TiO2 (6.0 mg Ti/m3 ~ 9.75 mg TiO2/m3), respectively. Each treatment group consisted of a minimum of 5 animals. Mice in the experimental groups received a single intratracheal instillation of 18 (low dose), 54 (medium dose) or 162 µg (high dose) of nano-TiO2 in a 40 µl suspension, followed by 150 μl air with a 250 µl SGE glass syringe (250F-LT-GT, MicroLab, Aarhus, Denmark). Intratracheal instillation was performed at 37 ºC on heating plates, under anesthesia using Hypnorm® (fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml from Janssen Pharma) and Dormicum® (Midazolam 5 mg/mL from Roche). Control mice received 40 µl of dispersant vehicle only. Following instillation, mice were under observation until they recovered from anaesthesia. Mice were allowed to recover for 24 hours, 3 days and 28 days following instillation before sacrificing under anaesthesia (Hypnorm/Dormicum). Blood, BAL fluid and tissues were collected. Lung tissues from each experimental and control mice were cut into small pieces, and stored in cryogenic vials and snap frozen immediately in liquid nitrogen. All tissues were stored at -80C until analysis.

tag: reference

tag: tissue

value: 11 mouse cell lines

source_name: Lung

tag: strain

value: Lung

tag: replicate

value: Biological replicate 2

tag: treatment

value: low dose sample

tag: time

value: harvested 1 day post-instillation


title: HCT116 siMYCLo-2-1 Cancer reference kit-2

country: USA

organism: Homo sapiens

tag: cell line

value: Colorectal cancer-derived HCT116 cell line


title: HCT116 siMYCLo-2-1 Cancer reference kit-3


title: Oct3/4KO Day1 biological rep2

status: Public on Oct 17 2013

city: Wako

first: Itoshi

last: NIKAIDO

state: Saitama

address: 2-1 Hirosawa

department: Center for Biosystems Dynamics Research

country: Japan

institute: RIKEN

description: On MEF feeders, with FGF4/heparin/Activin A

hyb_protocol: Samples were hybridized, stained, and washed according to the Expression Analysis Technical Manual (Affymetrix).

scan_protocol: Affymetrix GeneChip Scanner 3000 7G

data_processing:
The expression values were summarized and normalized by the robust multiarray analysis and quantile normalization method using by Expression Console(tm) software (Affymetrix).
MoEx-1_0-st-v1.r2.pgf
MoEx-1_0-st-v1.r2.dt1.mod.mm9.mps

label: biotin

source_name: ZHBTc4 ES cells, +Tet, Day 1

label_protocol: Samples were enzymatically fragmented and biotinylated using the WT Terminal Labeling Kit (Affymetrix).

growth_protocol: ES cells were maintained in GMEM supplemented with 10% FBS and 1,000 U/ml LIF on gelatin-coated dishes.

extract_protocol: Total RNA was isolated using QuickGene RNA cultured cell HC kit S (Fuji Film).

treatment_protocol: TS cells were induced in GMEM/10% FBS supplemented with 1 ug/ml Tet, 50 ng/ml human FGF4, 2 ug/ml heparin, 10 ng/ml human Activin A and 2 mM L-glutamine on MEF feeders.

value: Tet

value: 1 day


title: Day 1 Control 1

description: Biological replicate 1 of control sample, harvested 1 day post-instillation

value: Agilent Universal Mouse Reference RNA (UMRR)

value: Biological replicate 1

value: control sample


title: Oct3/4KO Day2 biological rep1

source_name: ZHBTc4 ES cells, +Tet, Day 2

value: 2 days


title: Day 1 Control 4

description: Biological replicate 4 of control sample, harvested 1 day post-instillation

value: Biological replicate 4


title: day3-CON-2

status: Public on Jul 03 2013

city: London

first: Nigel

middle: J

last: Gooderham

address: South Kensington Campus

department: Biomolecular Medicine

country: United Kingdom

institute: Imperial College London

description: Hepatic miRNA profile

hyb_protocol: Labelled RNA was hybridized to microarray slides using the Agilent complete labelling and hybridisation kit

scan_protocol: The slides were scanned using an Agilent scanner (G2505B) and the data were extracted using the Agilent Feature Extraction v.10.1 software.

data_processing: For each miRNA the raw data  were threshold to 1, log2 transformed, and normalized to the 75th percentile.  MiRNAs which were not flagged as present in at least 2 samples in any group were filtered out from further analysis

organism: Rattus norvegicus

source_name: liver

label_protocol: 100ng total RNA was labelled using the Agilent complete labelling and hybridisation kit

growth_protocol: Eight-week old male Fischer (F344) rats were obtained from Harlac Olac (Netherlands) and left to acclimatise for seven days prior to the commencement of the experiment. The animals were examined to ensure that they were physically and behaviourally normal. During the study the rats were kept at five animals per cage and under controlled lighting (12h light cycles), humidity (30-70%), air flow (15 changes per hour), and temperature (22±3 C). The rats were given access to mains water and powdered diet ad libitum. Animals were randomly assigned to cages and treatment groups based on their pre-experimental weight.

extract_protocol: Total RNA was extracted from 100mg of frozen liver sample using Trizol. The extracted RNA was evaluated as suitable for further analysis in it had an 260:280 ratio above two and a RIN number, as determined with on an Agilent bioanalyser, above eight.

treatment_protocol: Animals were dietary treated with 0, 50, 500 or 1000 ppm Phenobarbital

value: Fischer (F344)

tag: age

value: eight-weeks old

tag: gender

value: male

value: Liver

tag: phenobarbital dose (ppm)

tag: timepoint


title: Papillary glioneuronal [PGNT]

status: Public on Jul 29 2013

first: Denise

last: Sheer

address: Blizard Institute, 4 Newark Street

department: Neuroscience & Trauma

institute: Barts & The London School of Medicine & Dentistry

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: The data were normalised using quantile normalisation in GenomeStudio

source_name: Paediartric brain tumour PGNT

label_protocol: Cy3 Standard illumina prorocol

extract_protocol: RNA was extracted with QIAGEN miRNeasy mini kit in accordance with the prescribed protocol provided with the kit.

value: Papillary glioneuronal

tag: grade

value: I

tag: Sex

value: M


title: Leish_lesion_patient_2

status: Public on Jul 08 2013

city: Philadelphia

first: daniel

last: beiting

state: PA

address: 380 S. University Ave

department: Pathobiology

institute: University of Pennsylvania

data_processing: The data were quantile normalized without background subtraction using Illumina GenomeStudio V1.8

source_name: biopsy of cutaneous Leishmania braziliensis lesion

label_protocol: Biotin labeled complementary RNA (cRNA) was made using the Illumina TotalPrep RNA Amplification Kit

growth_protocol: Biopsies were directly preserved in RNAlater (Qiagen) and stored at -80c until the time of extraction

extract_protocol: Each biopsy was immersed in 1ml of Buffer RLT (Qiagen) and homogenized, on ice, using brief pulses with a rotor-stator.  Total RNA was isolated using the Qiagen Rneasy Plus kit.

value: L. braziliensis lesion


title: Leish_lesion_patient_4

treatment_protocol: Biopsies were directly preserved in RNAlater (Qiagen) and stored at -80c until the time of extraction


title: Norm_skin_patient_2

source_name: biopsy of normal skin

value: normal skin


title: Leish_lesion_patient_8


title: Norm_skin_patient_1


title: Leish_lesion_patient_1


title: Leish_lesion_patient_5


title: Control 9961.601503, Baseline visit

status: Public on Jun 17 2013

city: San Francisco

first: Sergio

middle: E

last: Baranzini

state: CA

address: 675 Nelson Rising Lane, Room S-215

department: Neurology

institute: University of California San Francisco

description:
9961.601503A.CEL
whole blood of healthy control, sample 9961.601503A, MS vs Ctrl Analysis, replication data set

hyb_protocol: 5.5ug of ssDNA was fragmented before hybridization using the Affymetrix GeneChip Hybridization, Wash and Stain Kit.

scan_protocol: Microarrays were scanned using the Affymetrix GeneChip Scanner 3000 7G.

data_processing:
Microarray data were processed in R using the R package “aroma.affymetrix”. Data were background corrected (“RMAbackgroundCorrection”) and quantile normalized before core probe sets were summarized to transcript level, using a custom made cdf file. This cdf file excludes all probes known to span single nucleotide polymorphisms (SNPs), which could interfere with hybridization and thus introduce noise (Duan, S., Zhang, W., Bleibel, W.K., Cox, N.J. and Dolan, M.E. (2008) SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation, 2, 469-470).
probe group file/meta-probeset file;
HuEx-1_0-st-v2,core,na31,hg19,HB20110919,noSNPs.cdf

label_protocol: 1ug of total RNA that had been put through the ribo minus protocol was labelled using the Affymetrix GeneChip WT Sense Target Labeling and Control Reagent kit.

extract_protocol: Blood was drawn into PAXgene collection tubes and RNA was isolated using the PAXgene Blood RNA kit (Qiagen, Valencia, CA), following manufacturer’s instructions except for an additional washing step before RNA elution. DNA was digested on columns using the RNase-free DNase Set (Qiagen, Valencia, CA).

tag: ID

value: female

tag: disease

value: Control

tag: visit

value: Baseline

value: untreated

value: whole blood

tag: data set

value: replication


title: Control 9961.601468, Baseline visit

description:
9961.601468A.CEL
whole blood of healthy control, sample 9961.601468A, MS vs Ctrl Analysis, replication data set


title: Leish_lesion_patient_6


title: Control 9961.601440, follow-up year 1 visit

description:
9961.601440B.CEL
whole blood of healthy control, sample 9961.601440B, MS vs Ctrl Analysis, replication data set

source_name: control_follow-up year 1_untreated

value: follow-up year 1


title: Control 9961.601497, Baseline visit

description:
9961.601497A.CEL
whole blood of healthy control, sample 9961.601497A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601431, Baseline visit

description:
9961.601431A.CEL
whole blood of healthy control, sample 9961.601431A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601440, Baseline visit

description:
9961.601440A.CEL
whole blood of healthy control, sample 9961.601440A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601468, follow-up year 1 visit

description:
9961.601468B.CEL
whole blood of healthy control, sample 9961.601468B, MS vs Ctrl Analysis, replication data set


title: Leish_lesion_patient_10


title: Leish_lesion_patient_9


title: Control 9961.601430, Baseline visit

description:
9961.601430A.CEL
whole blood of healthy control, sample 9961.601430A, MS vs Ctrl Analysis, replication data set


title: Leish_lesion_patient_7


title: Control 9961.601467, Baseline visit

description:
9961.601467A.CEL
whole blood of healthy control, sample 9961.601467A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601430, follow-up year 1 visit

description:
9961.601430B.CEL
whole blood of healthy control, sample 9961.601430B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601431, follow-up year 1 visit

description:
9961.601431B.CEL
whole blood of healthy control, sample 9961.601431B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601467, follow-up year 1 visit

description:
9961.601467B.CEL
whole blood of healthy control, sample 9961.601467B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601424, follow-up year 1 visit

description:
9961.601424B.CEL
whole blood of healthy control, sample 9961.601424B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601428, follow-up year 1 visit

description:
9961.601428B.CEL
whole blood of healthy control, sample 9961.601428B, MS vs Ctrl Analysis, replication data set


title: Leish_lesion_patient_3


title: Control 9961.601497, follow-up year 1 visit

description:
9961.601497B.CEL
whole blood of healthy control, sample 9961.601497B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601422, Baseline visit

description:
9961.601422A.CEL
whole blood of healthy control, sample 9961.601422A, MS vs Ctrl Analysis, replication data set


title: Control 600483.0100, Baseline visit

description:
600483.0100A.CEL
whole blood of healthy control, sample 600483.0100A, MS vs Ctrl Analysis, replication data set


title: Control 600483.0100, follow-up year 1 visit

description:
600483.0100B.CEL
whole blood of healthy control, sample 600483.0100B, MS vs Ctrl Analysis, replication data set


title: Control 41654.0100, follow-up year 1 visit

description:
41654.0100B.CEL
whole blood of healthy control, sample 41654.0100B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601370, Baseline visit

description:
9961.601370A.CEL
whole blood of healthy control, sample 9961.601370A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601333, follow-up year 1 visit

description:
9961.601333B.CEL
whole blood of healthy control, sample 9961.601333B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601388, Baseline visit

description:
9961.601388A.CEL
whole blood of healthy control, sample 9961.601388A, MS vs Ctrl Analysis, replication data set


title: Control 600419.0100, Baseline visit

description:
600419.0100A.CEL
whole blood of healthy control, sample 600419.0100A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601377, follow-up year 1 visit

description:
9961.601377B.CEL
whole blood of healthy control, sample 9961.601377B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601370, follow-up year 1 visit

description:
9961.601370B.CEL
whole blood of healthy control, sample 9961.601370B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601389, follow-up year 1 visit

description:
9961.601389B.CEL
whole blood of healthy control, sample 9961.601389B, MS vs Ctrl Analysis, replication data set


title: Control 41698.0100, follow-up year 1 visit

description:
41698.0100B.CEL
whole blood of healthy control, sample 41698.0100B, MS vs Ctrl Analysis, replication data set


title: Control 41616.0100, follow-up year 1 visit

description:
41616.0100B.CEL
whole blood of healthy control, sample 41616.0100B, MS vs Ctrl Analysis, replication data set


title: Control 41654.0100, Baseline visit

description:
41654.0100A.CEL
whole blood of healthy control, sample 41654.0100A, MS vs Ctrl Analysis, replication data set


title: Control 41698.0100, Baseline visit

description:
41698.0100A.CEL
whole blood of healthy control, sample 41698.0100A, MS vs Ctrl Analysis, replication data set


title: Control 41639.0100, Baseline visit

description:
41639.0100A.CEL
whole blood of healthy control, sample 41639.0100A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601388, follow-up year 1 visit

description:
9961.601388B.CEL
whole blood of healthy control, sample 9961.601388B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601371, Baseline visit

description:
9961.601371A.CEL
whole blood of healthy control, sample 9961.601371A, MS vs Ctrl Analysis, replication data set


title: Control 41639.0100, follow-up year 1 visit

description:
41639.0100B.CEL
whole blood of healthy control, sample 41639.0100B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601422, follow-up year 1 visit

description:
9961.601422B.CEL
whole blood of healthy control, sample 9961.601422B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601377, Baseline visit

description:
9961.601377A.CEL
whole blood of healthy control, sample 9961.601377A, MS vs Ctrl Analysis, replication data set


title: Control 41658.0100, follow-up year 1 visit

description:
41658.0100B.CEL
whole blood of healthy control, sample 41658.0100B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601333, Baseline visit

description:
9961.601333A.CEL
whole blood of healthy control, sample 9961.601333A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601389, Baseline visit

description:
9961.601389A.CEL
whole blood of healthy control, sample 9961.601389A, MS vs Ctrl Analysis, replication data set


title: Control 600402.0100, follow-up year 1 visit

description:
600402.0100B.CEL
whole blood of healthy control, sample 600402.0100B, MS vs Ctrl Analysis, replication data set


title: Control 600419.0100, follow-up year 1 visit

description:
600419.0100B.CEL
whole blood of healthy control, sample 600419.0100B, MS vs Ctrl Analysis, replication data set


title: Control 600385.0100, follow-up year 1 visit

description:
600385.0100B.CEL
whole blood of healthy control, sample 600385.0100B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601424, Baseline visit

description:
9961.601424A.CEL
whole blood of healthy control, sample 9961.601424A, MS vs Ctrl Analysis, replication data set


title: Control 41616.0100, Baseline visit

description:
41616.0100A.CEL
whole blood of healthy control, sample 41616.0100A, MS vs Ctrl Analysis, replication data set


title: Control 600385.0100, Baseline visit

description:
600385.0100A.CEL
whole blood of healthy control, sample 600385.0100A, MS vs Ctrl Analysis, replication data set


title: MS patient 600462.0001, follow-up year 1 visit [re-analysis]

description:
600462.0001B.CEL
whole blood of untreated MS patient, sample 600462.0001B, MS vs Ctrl Analysis, replication data set

source_name: MS patient_follow-up year 1_untreated

value: multiple sclerosis


title: MS patient 600505.0001, follow-up year 1 visit [re-analysis]

description:
600505.0001B.CEL
whole blood of untreated MS patient, sample 600505.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 41656.0001, follow-up year 1 visit [re-analysis]

description:
41656.0001B.CEL
whole blood of untreated MS patient, sample 41656.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 41656.0001, follow-up year 2 visit [re-analysis]

description:
41656.0001C.CEL
whole blood of untreated MS patient, sample 41656.0001C, MS vs Ctrl Analysis, replication data set

source_name: MS patient_follow-up year 2_untreated

value: follow-up year 2


title: MS patient 600347.0001, Baseline visit [re-analysis]

description:
600347.0001A.CEL
whole blood of untreated MS patient, sample 600347.0001A, MS vs Ctrl Analysis, replication data set

source_name: MS patient_Baseline_untreated


title: MS patient 41689.0001, Baseline visit [re-analysis]

description:
41689.0001A.CEL
whole blood of untreated MS patient, sample 41689.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41739.0001, follow-up year 2 visit [re-analysis]

description:
41739.0001C.CEL
whole blood of untreated MS patient, sample 41739.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600335.0001, Baseline visit [re-analysis]

description:
600335.0001A.CEL
whole blood of untreated MS patient, sample 600335.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600505.0001, Baseline visit [re-analysis]

description:
600505.0001A.CEL
whole blood of untreated MS patient, sample 600505.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41739.0001, Baseline visit [re-analysis]

description:
41739.0001A.CEL
whole blood of untreated MS patient, sample 41739.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41632.0001, follow-up year 2 visit [re-analysis]

description:
41632.0001C.CEL
whole blood of untreated MS patient, sample 41632.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600437.0001, follow-up year 1 visit [re-analysis]

description:
600437.0001B.CEL
whole blood of untreated MS patient, sample 600437.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600462.0001, Baseline visit [re-analysis]

description:
600462.0001A.CEL
whole blood of untreated MS patient, sample 600462.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41689.0001, follow-up year 1 visit [re-analysis]

description:
41689.0001B.CEL
whole blood of untreated MS patient, sample 41689.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600335.0001, follow-up year 2 visit [re-analysis]

description:
600335.0001C.CEL
whole blood of untreated MS patient, sample 600335.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600462.0001, follow-up year 2 visit [re-analysis]

description:
600462.0001C.CEL
whole blood of untreated MS patient, sample 600462.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 41656.0001, Baseline visit [re-analysis]

description:
41656.0001A.CEL
whole blood of untreated MS patient, sample 41656.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41739.0001, follow-up year 1 visit [re-analysis]

description:
41739.0001B.CEL
whole blood of untreated MS patient, sample 41739.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600347.0001, follow-up year 1 visit [re-analysis]

description:
600347.0001B.CEL
whole blood of untreated MS patient, sample 600347.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600445.0001, follow-up year 2 visit [re-analysis]

description:
600445.0001C.CEL
whole blood of untreated MS patient, sample 600445.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 41632.0001, Baseline visit [re-analysis]

description:
41632.0001A.CEL
whole blood of untreated MS patient, sample 41632.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600292.0001, follow-up year 1 visit [re-analysis]

description:
600292.0001B.CEL
whole blood of untreated MS patient, sample 600292.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600292.0001, Baseline visit [re-analysis]

description:
600292.0001A.CEL
whole blood of untreated MS patient, sample 600292.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600445.0001, follow-up year 1 visit [re-analysis]

description:
600445.0001B.CEL
whole blood of untreated MS patient, sample 600445.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600281.0001, Baseline visit [re-analysis]

description:
600281.0001A.CEL
whole blood of untreated MS patient, sample 600281.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600335.0001, follow-up year 1 visit [re-analysis]

description:
600335.0001B.CEL
whole blood of untreated MS patient, sample 600335.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 41632.0001, follow-up year 1 visit [re-analysis]

description:
41632.0001B.CEL
whole blood of untreated MS patient, sample 41632.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600279.0001, follow-up year 2 visit [re-analysis]

description:
600279.0001C.CEL
whole blood of untreated MS patient, sample 600279.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600257.0001, follow-up year 2 visit [re-analysis]

description:
600257.0001C.CEL
whole blood of untreated MS patient, sample 600257.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600257.0001, follow-up year 1 visit [re-analysis]

description:
600257.0001B.CEL
whole blood of untreated MS patient, sample 600257.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600245.0001, Baseline visit [re-analysis]

description:
600245.0001A.CEL
whole blood of untreated MS patient, sample 600245.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600257.0001, Baseline visit [re-analysis]

description:
600257.0001A.CEL
whole blood of untreated MS patient, sample 600257.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41743.0001, follow-up year 1 visit [re-analysis]

description:
41743.0001B.CEL
whole blood of untreated MS patient, sample 41743.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600229.0001, follow-up year 2 visit [re-analysis]

description:
600229.0001C.CEL
whole blood of untreated MS patient, sample 600229.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600245.0001, follow-up year 2 visit [re-analysis]

description:
600245.0001C.CEL
whole blood of untreated MS patient, sample 600245.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600245.0001, follow-up year 1 visit [re-analysis]

description:
600245.0001B.CEL
whole blood of untreated MS patient, sample 600245.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 41567.0001, Baseline visit [re-analysis]

description:
41567.0001A.CEL
whole blood of untreated MS patient, sample 41567.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41743.0001, Baseline visit [re-analysis]

description:
41743.0001A.CEL
whole blood of untreated MS patient, sample 41743.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 610039.0001, follow-up year 1 visit [re-analysis]

description:
610039.0001B.CEL
whole blood of untreated MS patient, sample 610039.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600189.0001, follow-up year 2 visit [re-analysis]

description:
600189.0001C.CEL
whole blood of untreated MS patient, sample 600189.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600188.0001, follow-up year 2 visit [re-analysis]

description:
600188.0001C.CEL
whole blood of untreated MS patient, sample 600188.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600076.0001, follow-up year 2 visit [re-analysis]

description:
600076.0001C.CEL
whole blood of untreated MS patient, sample 600076.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600189.0001, follow-up year 1 visit [re-analysis]

description:
600189.0001B.CEL
whole blood of untreated MS patient, sample 600189.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600089.0001, Baseline visit [re-analysis]

description:
600089.0001A.CEL
whole blood of untreated MS patient, sample 600089.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41743.0001, follow-up year 2 visit [re-analysis]

description:
41743.0001C.CEL
whole blood of untreated MS patient, sample 41743.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600188.0001, follow-up year 1 visit [re-analysis]

description:
600188.0001B.CEL
whole blood of untreated MS patient, sample 600188.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 41495.0001, follow-up year 2 visit [re-analysis]

description:
41495.0001C.CEL
whole blood of untreated MS patient, sample 41495.0001C, MS vs Ctrl Analysis, replication data set


title: MS patient 600183.0001, Baseline visit [re-analysis]

description:
600183.0001A.CEL
whole blood of untreated MS patient, sample 600183.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 41495.0001, follow-up year 1 visit [re-analysis]

description:
41495.0001B.CEL
whole blood of untreated MS patient, sample 41495.0001B, MS vs Ctrl Analysis, replication data set


title: MS patient 600001.0001, Baseline visit [re-analysis]

description:
600001.0001A.CEL
whole blood of untreated MS patient, sample 600001.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600001.0001, follow-up year 1 visit [re-analysis]

description:
600001.0001B.CEL
whole blood of untreated MS patient, sample 600001.0001B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601498, follow-up year 1 visit

description:
9961.601498C.CEL
whole blood of healthy control, sample 9961.601498C, MS vs Ctrl Analysis, discovery data set

data_processing:
Microarray data were processed in R using the R package aroma.affymetrix. Data were background corrected (RMAbackgroundCorrection) and quantile normalized before core probe sets were summarized to transcript level, using a custom made cdf file. This cdf file excludes all probes known to span single nucleotide polymorphisms (SNPs), which could interfere with hybridization and thus introduce noise (Duan, S., Zhang, W., Bleibel, W.K., Cox, N.J. and Dolan, M.E. (2008) SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation, 2, 469-470).
probe group file/meta-probeset file;
HuEx-1_0-st-v2,core,na31,hg19,HB20110919,noSNPs.cdf

value: discovery


title: Control 9961.601499, follow-up year 1 visit

description:
9961.601499C.CEL
whole blood of healthy control, sample 9961.601499C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41495.0001, Baseline visit [re-analysis]

description:
41495.0001A.CEL
whole blood of untreated MS patient, sample 41495.0001A, MS vs Ctrl Analysis, replication data set


title: MS patient 600182.0001, Baseline visit [re-analysis]

description:
600182.0001A.CEL
whole blood of untreated MS patient, sample 600182.0001A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601495, follow-up year 1 visit

description:
9961.601495C.CEL
whole blood of healthy control, sample 9961.601495C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601488, follow-up year 1 visit

description:
9961.601488C.CEL
whole blood of healthy control, sample 9961.601488C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601492, follow-up year 1 visit

description:
9961.601492C.CEL
whole blood of healthy control, sample 9961.601492C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601492, Baseline visit

description:
9961.601492B.CEL
whole blood of healthy control, sample 9961.601492B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600188.0001, Baseline visit [re-analysis]

description:
600188.0001A.CEL
whole blood of untreated MS patient, sample 600188.0001A, MS vs Ctrl Analysis, replication data set


title: Control 9961.601495, Baseline visit

description:
9961.601495B.CEL
whole blood of healthy control, sample 9961.601495B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601483, follow-up year 1 visit

description:
9961.601483C.CEL
whole blood of healthy control, sample 9961.601483C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601498, Baseline visit

description:
9961.601498B.CEL
whole blood of healthy control, sample 9961.601498B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601480, follow-up year 1 visit

description:
9961.601480C.CEL
whole blood of healthy control, sample 9961.601480C, MS vs Ctrl Analysis, discovery data set


title: Control 41196.0100, follow-up year 1 visit

description:
41196.0100C.CEL
whole blood of healthy control, sample 41196.0100C, MS vs Ctrl Analysis, discovery data set

value: male


title: Control 9961.601480, Baseline visit

description:
9961.601480B.CEL
whole blood of healthy control, sample 9961.601480B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601488, Baseline visit

description:
9961.601488B.CEL
whole blood of healthy control, sample 9961.601488B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601471, follow-up year 1 visit

description:
9961.601471C.CEL
whole blood of healthy control, sample 9961.601471C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601499, Baseline visit

description:
9961.601499B.CEL
whole blood of healthy control, sample 9961.601499B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601477, Baseline visit

description:
9961.601477B.CEL
whole blood of healthy control, sample 9961.601477B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601482, Baseline visit

description:
9961.601482B.CEL
whole blood of healthy control, sample 9961.601482B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601482, follow-up year 1 visit

description:
9961.601482C.CEL
whole blood of healthy control, sample 9961.601482C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601477, follow-up year 1 visit

description:
9961.601477C.CEL
whole blood of healthy control, sample 9961.601477C, MS vs Ctrl Analysis, discovery data set


title: Control 41196.0100, Baseline visit

description:
41196.0100B.CEL
whole blood of healthy control, sample 41196.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601483, Baseline visit

description:
9961.601483B.CEL
whole blood of healthy control, sample 9961.601483B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601471, Baseline visit

description:
9961.601471B.CEL
whole blood of healthy control, sample 9961.601471B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601470, follow-up year 1 visit

description:
9961.601470C.CEL
whole blood of healthy control, sample 9961.601470C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601470, Baseline visit

description:
9961.601470B.CEL
whole blood of healthy control, sample 9961.601470B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601453, Baseline visit

description:
9961.601453B.CEL
whole blood of healthy control, sample 9961.601453B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601503, follow-up year 1 visit

description:
9961.601503B.CEL
whole blood of healthy control, sample 9961.601503B, MS vs Ctrl Analysis, replication data set


title: Control 9961.601462, Baseline visit

description:
9961.601462B.CEL
whole blood of healthy control, sample 9961.601462B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601462, follow-up year 1 visit

description:
9961.601462C.CEL
whole blood of healthy control, sample 9961.601462C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601445, follow-up year 1 visit

description:
9961.601445C.CEL
whole blood of healthy control, sample 9961.601445C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601436, follow-up year 1 visit

description:
9961.601436B.CEL
whole blood of healthy control, sample 9961.601436B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601445, Baseline visit

description:
9961.601445B.CEL
whole blood of healthy control, sample 9961.601445B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601401, follow-up year 1 visit

description:
9961.601401B.CEL
whole blood of healthy control, sample 9961.601401B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601436, Baseline visit

description:
9961.601436A.CEL
whole blood of healthy control, sample 9961.601436A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601412, Baseline visit

description:
9961.601412A.CEL
whole blood of healthy control, sample 9961.601412A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601421, follow-up year 1 visit

description:
9961.601421B.CEL
whole blood of healthy control, sample 9961.601421B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601407, follow-up year 1 visit

description:
9961.601407B.CEL
whole blood of healthy control, sample 9961.601407B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601426, Baseline visit

description:
9961.601426A.CEL
whole blood of healthy control, sample 9961.601426A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601407, Baseline visit

description:
9961.601407A.CEL
whole blood of healthy control, sample 9961.601407A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601421, Baseline visit

description:
9961.601421A.CEL
whole blood of healthy control, sample 9961.601421A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601376, follow-up year 1 visit

description:
9961.601376B.CEL
whole blood of healthy control, sample 9961.601376B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601380, Baseline visit

description:
9961.601380A.CEL
whole blood of healthy control, sample 9961.601380A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601401, Baseline visit

description:
9961.601401A.CEL
whole blood of healthy control, sample 9961.601401A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601387, follow-up year 1 visit

description:
9961.601387B.CEL
whole blood of healthy control, sample 9961.601387B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601380, follow-up year 1 visit

description:
9961.601380B.CEL
whole blood of healthy control, sample 9961.601380B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601420, follow-up year 1 visit

description:
9961.601420B.CEL
whole blood of healthy control, sample 9961.601420B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601435, follow-up year 1 visit

description:
9961.601435B.CEL
whole blood of healthy control, sample 9961.601435B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601426, follow-up year 1 visit

description:
9961.601426B.CEL
whole blood of healthy control, sample 9961.601426B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601376, Baseline visit

description:
9961.601376A.CEL
whole blood of healthy control, sample 9961.601376A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601420, Baseline visit

description:
9961.601420A.CEL
whole blood of healthy control, sample 9961.601420A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601367, follow-up year 1 visit

description:
9961.601367B.CEL
whole blood of healthy control, sample 9961.601367B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601363, follow-up year 1 visit

description:
9961.601363C.CEL
whole blood of healthy control, sample 9961.601363C, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601360, follow-up year 1 visit

description:
9961.601360B.CEL
whole blood of healthy control, sample 9961.601360B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601435, Baseline visit

description:
9961.601435A.CEL
whole blood of healthy control, sample 9961.601435A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601354, Baseline visit

description:
9961.601354A.CEL
whole blood of healthy control, sample 9961.601354A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601412, follow-up year 1 visit

description:
9961.601412B.CEL
whole blood of healthy control, sample 9961.601412B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601354, follow-up year 1 visit

description:
9961.601354B.CEL
whole blood of healthy control, sample 9961.601354B, MS vs Ctrl Analysis, discovery data set


title: Control 600478.0100, Baseline visit

description:
600478.0100B.CEL
whole blood of healthy control, sample 600478.0100A, MS vs Ctrl Analysis, discovery data set


title: Control 600341.0100, Baseline visit

description:
600341.0100A.CEL
whole blood of healthy control, sample 600341.0100A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601332, follow-up year 1 visit

description:
9961.601332B.CEL
whole blood of healthy control, sample 9961.601332B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601351, follow-up year 1 visit

description:
9961.601351B.CEL
whole blood of healthy control, sample 9961.601351B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601360, Baseline visit

description:
9961.601360A.CEL
whole blood of healthy control, sample 9961.601360A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601351, Baseline visit

description:
9961.601351A.CEL
whole blood of healthy control, sample 9961.601351A, MS vs Ctrl Analysis, discovery data set


title: Control 600341.0100, follow-up year 1 visit

description:
600341.0100B.CEL
whole blood of healthy control, sample 600341.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 600413.0100, follow-up year 1 visit

description:
600413.0100B.CEL
whole blood of healthy control, sample 600413.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601321, follow-up year 1 visit

description:
9961.601321B.CEL
whole blood of healthy control, sample 9961.601321B, MS vs Ctrl Analysis, discovery data set


title: Control 600478.0100, follow-up year 1 visit

description:
600478.0100A.CEL
whole blood of healthy control, sample 600478.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601332, Baseline visit

description:
9961.601332A.CEL
whole blood of healthy control, sample 9961.601332A, MS vs Ctrl Analysis, discovery data set


title: Control 600413.0100, Baseline visit

description:
600413.0100A.CEL
whole blood of healthy control, sample 600413.0100A, MS vs Ctrl Analysis, discovery data set


title: Control 41463.0100, follow-up year 1 visit

description:
41463.0100B.CEL
whole blood of healthy control, sample 41463.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 41463.0100, Baseline visit

description:
41463.0100A.CEL
whole blood of healthy control, sample 41463.0100A, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601263, follow-up year 1 visit

description:
9961.601263B.CEL
whole blood of healthy control, sample 9961.601263B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601263, Baseline visit

description:
9961.601263A.CEL
whole blood of healthy control, sample 9961.601263A, MS vs Ctrl Analysis, discovery data set


title: Control 41634.0100, follow-up year 1 visit

description:
41634.0100B.CEL
whole blood of healthy control, sample 41634.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601321, Baseline visit

description:
9961.601321A.CEL
whole blood of healthy control, sample 9961.601321A, MS vs Ctrl Analysis, discovery data set


title: Control 41634.0100, Baseline visit

description:
41634.0100A.CEL
whole blood of healthy control, sample 41634.0100A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600445.0001, Baseline visit [re-analysis]

description:
600445.0001A.CEL
whole blood of untreated MS patient, sample 600445.0001A, MS vs Ctrl Analysis, replication data set


title: Control 600355.0100, follow-up year 1 visit

description:
600355.0100B.CEL
whole blood of healthy control, sample 600355.0100B, MS vs Ctrl Analysis, discovery data set


title: Control 600355.0100, Baseline visit

description:
600355.0100A.CEL
whole blood of healthy control, sample 600355.0100A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600229.0001, follow-up year 1 visit [re-analysis]

description:
600229.0001B.CEL
whole blood of untreated MS patient, sample 600229.0001B, MS vs Ctrl Analysis, replication data set


title: Control 600239.0100, Baseline visit

description:
600239.0100A.CEL
whole blood of healthy control, sample 600239.0100A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600469.0001, follow-up year 2 visit [re-analysis]

description:
600469.0001C.CEL
whole blood of untreated MS patient, sample 600469.0001C, MS vs Ctrl Analysis, discovery data set


title: Control 600239.0100, follow-up year 1 visit

description:
600239.0100B.CEL
whole blood of healthy control, sample 600239.0100B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41671.0001, follow-up year 2 visit [re-analysis]

description:
41671.0001C.CEL
whole blood of untreated MS patient, sample 41671.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600457.0001, follow-up year 1 visit [re-analysis]

description:
600457.0001B.CEL
whole blood of untreated MS patient, sample 600457.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41671.0001, Baseline visit [re-analysis]

description:
41671.0001A.CEL
whole blood of untreated MS patient, sample 41671.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600457.0001, Baseline visit [re-analysis]

description:
600457.0001A.CEL
whole blood of untreated MS patient, sample 600457.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 40061.0001, Baseline visit [re-analysis]

description:
40061.0001A.CEL
whole blood of untreated MS patient, sample 40061.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600441.0001, follow-up year 1 visit [re-analysis]

description:
600441.0001B.CEL
whole blood of untreated MS patient, sample 600441.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600469.0001, Baseline visit [re-analysis]

description:
600469.0001A.CEL
whole blood of untreated MS patient, sample 600469.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600457.0001, follow-up year 2 visit [re-analysis]

description:
600457.0001C.CEL
whole blood of untreated MS patient, sample 600457.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41671.0001, follow-up year 1 visit [re-analysis]

description:
41671.0001B.CEL
whole blood of untreated MS patient, sample 41671.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41826.0001, Baseline visit [re-analysis]

description:
41826.0001A.CEL
whole blood of untreated MS patient, sample 41826.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600441.0001, Baseline visit [re-analysis]

description:
600441.0001A.CEL
whole blood of untreated MS patient, sample 600441.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41654.0001, follow-up year 1 visit [re-analysis]

description:
41654.0001B.CEL
whole blood of untreated MS patient, sample 41654.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41826.0001, follow-up year 1 visit [re-analysis]

description:
41826.0001B.CEL
whole blood of untreated MS patient, sample 41826.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41655.0001, follow-up year 1 visit [re-analysis]

description:
41655.0001B.CEL
whole blood of untreated MS patient, sample 41655.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600441.0001, follow-up year 2 visit [re-analysis]

description:
600441.0001C.CEL
whole blood of untreated MS patient, sample 600441.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 40061.0001, follow-up year 2 visit [re-analysis]

description:
40061.0001C.CEL
whole blood of untreated MS patient, sample 40061.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600392.0001, follow-up year 2 visit [re-analysis]

description:
600392.0001C.CEL
whole blood of untreated MS patient, sample 600392.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 40061.0001, follow-up year 1 visit [re-analysis]

description:
40061.0001B.CEL
whole blood of untreated MS patient, sample 40061.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41826.0001, follow-up year 2 visit [re-analysis]

description:
41826.0001C.CEL
whole blood of untreated MS patient, sample 41826.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41654.0001, Baseline visit [re-analysis]

description:
41654.0001A.CEL
whole blood of untreated MS patient, sample 41654.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41655.0001, Baseline visit [re-analysis]

description:
41655.0001A.CEL
whole blood of untreated MS patient, sample 41655.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600392.0001, Baseline visit [re-analysis]

description:
600392.0001A.CEL
whole blood of untreated MS patient, sample 600392.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600391.0001, follow-up year 2 visit [re-analysis]

description:
600391.0001C.CEL
whole blood of untreated MS patient, sample 600391.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41829.0001, Baseline visit [re-analysis]

description:
41829.0001A.CEL
whole blood of untreated MS patient, sample 41829.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600391.0001, follow-up year 1 visit [re-analysis]

description:
600391.0001B.CEL
whole blood of untreated MS patient, sample 600391.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600392.0001, follow-up year 1 visit [re-analysis]

description:
600392.0001B.CEL
whole blood of untreated MS patient, sample 600392.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600391.0001, Baseline visit [re-analysis]

description:
600391.0001A.CEL
whole blood of untreated MS patient, sample 600391.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600360.0001, follow-up year 2 visit [re-analysis]

description:
600360.0001C.CEL
whole blood of untreated MS patient, sample 600360.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41655.0001, follow-up year 2 visit [re-analysis]

description:
41655.0001C.CEL
whole blood of untreated MS patient, sample 41655.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41165.0001, Baseline visit [re-analysis]

description:
41165.0001A.CEL
whole blood of untreated MS patient, sample 41165.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41165.0001, follow-up year 1 visit [re-analysis]

description:
41165.0001B.CEL
whole blood of untreated MS patient, sample 41165.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41616.0001, follow-up year 1 visit [re-analysis]

description:
41616.0001B.CEL
whole blood of untreated MS patient, sample 41616.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600340.0001, follow-up year 1 visit [re-analysis]

description:
600340.0001B.CEL
whole blood of untreated MS patient, sample 600340.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41626.0001, Baseline visit [re-analysis]

description:
41626.0001A.CEL
whole blood of untreated MS patient, sample 41626.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600340.0001, Baseline visit [re-analysis]

description:
600340.0001A.CEL
whole blood of untreated MS patient, sample 600340.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41626.0001, follow-up year 2 visit [re-analysis]

description:
41626.0001C.CEL
whole blood of untreated MS patient, sample 41626.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600340.0001, follow-up year 2 visit [re-analysis]

description:
600340.0001C.CEL
whole blood of untreated MS patient, sample 600340.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600327.0001, follow-up year 2 visit [re-analysis]

description:
600327.0001C.CEL
whole blood of untreated MS patient, sample 600327.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600327.0001, follow-up year 1 visit [re-analysis]

description:
600327.0001B.CEL
whole blood of untreated MS patient, sample 600327.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600337.0001, follow-up year 1 visit [re-analysis]

description:
600337.0001B.CEL
whole blood of untreated MS patient, sample 600337.0001B, MS vs Ctrl Analysis, discovery data set


title: Control 9961.601453, follow-up year 1 visit

description:
9961.601453C.CEL
whole blood of healthy control, sample 9961.601453C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600311.0001, follow-up year 2 visit [re-analysis]

description:
600311.0001C.CEL
whole blood of untreated MS patient, sample 600311.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41643.0001, Baseline visit [re-analysis]

description:
41643.0001A.CEL
whole blood of untreated MS patient, sample 41643.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600360.0001, Baseline visit [re-analysis]

description:
600360.0001A.CEL
whole blood of untreated MS patient, sample 600360.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41599.0001, follow-up year 2 visit [re-analysis]

description:
41599.0001C.CEL
whole blood of untreated MS patient, sample 41599.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600360.0001, follow-up year 1 visit [re-analysis]

description:
600360.0001B.CEL
whole blood of untreated MS patient, sample 600360.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600337.0001, Baseline visit [re-analysis]

description:
600337.0001A.CEL
whole blood of untreated MS patient, sample 600337.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600311.0001, follow-up year 1 visit [re-analysis]

description:
600311.0001B.CEL
whole blood of untreated MS patient, sample 600311.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600302.0001, follow-up year 1 visit [re-analysis]

description:
600302.0001B.CEL
whole blood of untreated MS patient, sample 600302.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41599.0001, Baseline visit [re-analysis]

description:
41599.0001A.CEL
whole blood of untreated MS patient, sample 41599.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600302.0001, follow-up year 2 visit [re-analysis]

description:
600302.0001C.CEL
whole blood of untreated MS patient, sample 600302.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41599.0001, follow-up year 1 visit [re-analysis]

description:
41599.0001B.CEL
whole blood of untreated MS patient, sample 41599.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600302.0001, Baseline visit [re-analysis]

description:
600302.0001A.CEL
whole blood of untreated MS patient, sample 600302.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41716.0001, Baseline visit [re-analysis]

description:
41716.0001A.CEL
whole blood of untreated MS patient, sample 41716.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 40072.0001, follow-up year 1 visit [re-analysis]

description:
40072.0001B.CEL
whole blood of untreated MS patient, sample 40072.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41626.0001, follow-up year 1 visit [re-analysis]

description:
41626.0001B.CEL
whole blood of untreated MS patient, sample 41626.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41596.0001, Baseline visit [re-analysis]

description:
41596.0001A.CEL
whole blood of untreated MS patient, sample 41596.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41586.0001, follow-up year 1 visit [re-analysis]

description:
41586.0001B.CEL
whole blood of untreated MS patient, sample 41586.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41627.0001, follow-up year 2 visit [re-analysis]

description:
41627.0001C.CEL
whole blood of untreated MS patient, sample 41627.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41627.0001, follow-up year 1 visit [re-analysis]

description:
41627.0001B.CEL
whole blood of untreated MS patient, sample 41627.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600271.0001, follow-up year 1 visit [re-analysis]

description:
600271.0001B.CEL
whole blood of untreated MS patient, sample 600271.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600273.0001, follow-up year 1 visit [re-analysis]

description:
600273.0001B.CEL
whole blood of untreated MS patient, sample 600273.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600242.0001, Baseline visit [re-analysis]

description:
600242.0001A.CEL
whole blood of untreated MS patient, sample 600242.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600273.0001, Baseline visit [re-analysis]

description:
600273.0001A.CEL
whole blood of untreated MS patient, sample 600273.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600271.0001, Baseline visit [re-analysis]

description:
600271.0001A.CEL
whole blood of untreated MS patient, sample 600271.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600242.0001, follow-up year 1 visit [re-analysis]

description:
600242.0001B.CEL
whole blood of untreated MS patient, sample 600242.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600267.0001, Baseline visit [re-analysis]

description:
600267.0001A.CEL
whole blood of untreated MS patient, sample 600267.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41627.0001, Baseline visit [re-analysis]

description:
41627.0001A.CEL
whole blood of untreated MS patient, sample 41627.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600222.0001, Baseline visit [re-analysis]

description:
600222.0001A.CEL
whole blood of untreated MS patient, sample 600222.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41593.0001, follow-up year 2 visit [re-analysis]

description:
41593.0001C.CEL
whole blood of untreated MS patient, sample 41593.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600218.0001, follow-up year 1 visit [re-analysis]

description:
600218.0001B.CEL
whole blood of untreated MS patient, sample 600218.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600242.0001, follow-up year 2 visit [re-analysis]

description:
600242.0001C.CEL
whole blood of untreated MS patient, sample 600242.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41572.0001, Baseline visit [re-analysis]

description:
41572.0001A.CEL
whole blood of untreated MS patient, sample 41572.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600222.0001, follow-up year 2 visit [re-analysis]

description:
600222.0001C.CEL
whole blood of untreated MS patient, sample 600222.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600223.0001, follow-up year 2 visit [re-analysis]

description:
600223.0001C.CEL
whole blood of untreated MS patient, sample 600223.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600218.0001, Baseline visit [re-analysis]

description:
600218.0001A.CEL
whole blood of untreated MS patient, sample 600218.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600209.0001, follow-up year 2 visit [re-analysis]

description:
600209.0001C.CEL
whole blood of untreated MS patient, sample 600209.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41556.0001, Baseline visit [re-analysis]

description:
41556.0001A.CEL
whole blood of untreated MS patient, sample 41556.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600271.0001, follow-up year 2 visit [re-analysis]

description:
600271.0001C.CEL
whole blood of untreated MS patient, sample 600271.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600327.0001, Baseline visit [re-analysis]

description:
600327.0001A.CEL
whole blood of untreated MS patient, sample 600327.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600218.0001, follow-up year 2 visit [re-analysis]

description:
600218.0001C.CEL
whole blood of untreated MS patient, sample 600218.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41593.0001, Baseline visit [re-analysis]

description:
41593.0001A.CEL
whole blood of untreated MS patient, sample 41593.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600273.0001, follow-up year 2 visit [re-analysis]

description:
600273.0001C.CEL
whole blood of untreated MS patient, sample 600273.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600209.0001, follow-up year 1 visit [re-analysis]

description:
600209.0001B.CEL
whole blood of untreated MS patient, sample 600209.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41531.0001, follow-up year 2 visit [re-analysis]

description:
41531.0001C.CEL
whole blood of untreated MS patient, sample 41531.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600209.0001, Baseline visit [re-analysis]

description:
600209.0001A.CEL
whole blood of untreated MS patient, sample 600209.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41534.0001, Baseline visit [re-analysis]

description:
41534.0001A.CEL
whole blood of untreated MS patient, sample 41534.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41556.0001, follow-up year 1 visit [re-analysis]

description:
41556.0001B.CEL
whole blood of untreated MS patient, sample 41556.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41531.0001, follow-up year 1 visit [re-analysis]

description:
41531.0001B.CEL
whole blood of untreated MS patient, sample 41531.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41549.0001, Baseline visit [re-analysis]

description:
41549.0001A.CEL
whole blood of untreated MS patient, sample 41549.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41530.0001, Baseline visit [re-analysis]

description:
41530.0001A.CEL
whole blood of untreated MS patient, sample 41530.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41531.0001, Baseline visit [re-analysis]

description:
41531.0001A.CEL
whole blood of untreated MS patient, sample 41531.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600162.0001, follow-up year 2 visit [re-analysis]

description:
600162.0001C.CEL
whole blood of untreated MS patient, sample 600162.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600161.0001, follow-up year 2 visit [re-analysis]

description:
600161.0001C.CEL
whole blood of untreated MS patient, sample 600161.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600161.0001, follow-up year 1 visit [re-analysis]

description:
600161.0001B.CEL
whole blood of untreated MS patient, sample 600161.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600161.0001, Baseline visit [re-analysis]

description:
600161.0001A.CEL
whole blood of untreated MS patient, sample 600161.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600162.0001, Baseline visit [re-analysis]

description:
600162.0001A.CEL
whole blood of untreated MS patient, sample 600162.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41293.0001, follow-up year 2 visit [re-analysis]

description:
41293.0001C.CEL
whole blood of untreated MS patient, sample 41293.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600153.0001, follow-up year 1 visit [re-analysis]

description:
600153.0001B.CEL
whole blood of untreated MS patient, sample 600153.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41293.0001, follow-up year 1 visit [re-analysis]

description:
41293.0001B.CEL
whole blood of untreated MS patient, sample 41293.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600166.0001, Baseline visit [re-analysis]

description:
600166.0001A.CEL
whole blood of untreated MS patient, sample 600166.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600141.0001, follow-up year 1 visit [re-analysis]

description:
600141.0001B.CEL
whole blood of untreated MS patient, sample 600141.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600162.0001, follow-up year 1 visit [re-analysis]

description:
600162.0001B.CEL
whole blood of untreated MS patient, sample 600162.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600139.0001, follow-up year 1 visit [re-analysis]

description:
600139.0001B.CEL
whole blood of untreated MS patient, sample 600139.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600166.0001, follow-up year 1 visit [re-analysis]

description:
600166.0001B.CEL
whole blood of untreated MS patient, sample 600166.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600153.0001, follow-up year 2 visit [re-analysis]

description:
600153.0001C.CEL
whole blood of untreated MS patient, sample 600153.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600139.0001, follow-up year 2 visit [re-analysis]

description:
600139.0001C.CEL
whole blood of untreated MS patient, sample 600139.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600166.0001, follow-up year 2 visit [re-analysis]

description:
600166.0001C.CEL
whole blood of untreated MS patient, sample 600166.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600134.0001, follow-up year 1 visit [re-analysis]

description:
600134.0001B.CEL
whole blood of untreated MS patient, sample 600134.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600134.0001, follow-up year 2 visit [re-analysis]

description:
600134.0001C.CEL
whole blood of untreated MS patient, sample 600134.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600134.0001, Baseline visit [re-analysis]

description:
600134.0001A.CEL
whole blood of untreated MS patient, sample 600134.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600104.0001, Baseline visit [re-analysis]

description:
600104.0001A.CEL
whole blood of untreated MS patient, sample 600104.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41510.0001, Baseline visit [re-analysis]

description:
41510.0001A.CEL
whole blood of untreated MS patient, sample 41510.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600130.0001, follow-up year 1 visit [re-analysis]

description:
600130.0001B.CEL
whole blood of untreated MS patient, sample 600130.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 600096.0001, follow-up year 2 visit [re-analysis]

description:
600096.0001C.CEL
whole blood of untreated MS patient, sample 600096.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600153.0001, Baseline visit [re-analysis]

description:
600153.0001A.CEL
whole blood of untreated MS patient, sample 600153.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41527.0001, follow-up year 2 visit [re-analysis]

description:
41527.0001C.CEL
whole blood of untreated MS patient, sample 41527.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600096.0001, Baseline visit [re-analysis]

description:
600096.0001A.CEL
whole blood of untreated MS patient, sample 600096.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41509.0001, Baseline visit [re-analysis]

description:
41509.0001A.CEL
whole blood of untreated MS patient, sample 41509.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600009.0001, Baseline visit [re-analysis]

description:
600009.0001A.CEL
whole blood of untreated MS patient, sample 600009.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600029.0001, Baseline visit [re-analysis]

description:
600029.0001A.CEL
whole blood of untreated MS patient, sample 600029.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600009.0001, follow-up year 1 visit [re-analysis]

description:
600009.0001B.CEL
whole blood of untreated MS patient, sample 600009.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41509.0001, follow-up year 1 visit [re-analysis]

description:
41509.0001B.CEL
whole blood of untreated MS patient, sample 41509.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 600505.0001, follow-up year 1 visit

description:
600505.0001B.CEL
whole blood of untreated MS patient, sample 600505.0001B, Interferon Analysis, replication data set

data_processing:
Microarray data were processed in R using the R package aroma.affymetrix. Data were background corrected (RMAbackgroundCorrection) and quantile normalized before core probe sets were summarized to transcript level, using a custom made cdf file. This cdf file excludes all probes known to span single nucleotide polymorphisms (SNPs), which could interfere with hybridization and thus introduce noise (Duan, S., Zhang, W., Bleibel, W.K., Cox, N.J. and Dolan, M.E. (2008) SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs. Bioinformation, 2, 469-470).
probe group file: HuEx-1_0-st-v2,core,na31,hg19,HB20110919,noSNPs.cdf
meta-probeset file: HuEx-1_0-st-v2,core,na31,hg19,HB20110919,noSNPs.cdf

source_name: MS patient_untreated_follow-up year 1


title: MS patient 41497.0001, Baseline visit [re-analysis]

description:
41497.0001A.CEL
whole blood of untreated MS patient, sample 41497.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600096.0001, follow-up year 1 visit [re-analysis]

description:
600096.0001B.CEL
whole blood of untreated MS patient, sample 600096.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41689.0001, follow-up year 1 visit

description:
41689.0001B.CEL
whole blood of untreated MS patient, sample 41689.0001B, Interferon Analysis, replication data set


title: MS patient 41497.0001, follow-up year 2 visit [re-analysis]

description:
41497.0001C.CEL
whole blood of untreated MS patient, sample 41497.0001C, MS vs Ctrl Analysis, discovery data set


title: MS patient 41293.0001, Baseline visit [re-analysis]

description:
41293.0001A.CEL
whole blood of untreated MS patient, sample 41293.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600139.0001, Baseline visit [re-analysis]

description:
600139.0001A.CEL
whole blood of untreated MS patient, sample 600139.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41790.0001, Baseline visit

description:
41790.0001A.CEL
whole blood of Interferon treated MS patient, sample 41790.0001A, Interferon Analysis, replication data set

source_name: MS patient_Interferon_Baseline

value: Interferon - Avonex


title: MS patient 41689.0001, follow-up year 2 visit

description:
41689.0001C.CEL
whole blood of Interferon treated MS patient, sample 41689.0001C, Interferon Analysis, replication data set

source_name: MS patient_Interferon_follow-up year 2

value: Interferon - Rebif


title: MS patient 600498.0001, follow-up year 1 visit

description:
600498.0001B.CEL
whole blood of Interferon treated MS patient, sample 600498.0001B, Interferon Analysis, replication data set

source_name: MS patient_Interferon_follow-up year 1


title: MS patient 41509.0001, follow-up year 2 visit [re-analysis]

description:
41509.0001C.CEL
whole blood of untreated MS patient, sample 41509.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41461.0001, Baseline visit [re-analysis]

description:
41461.0001A.CEL
whole blood of untreated MS patient, sample 41461.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 41485.0001, Baseline visit [re-analysis]

description:
41485.0001A.CEL
whole blood of untreated MS patient, sample 41485.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600498.0001, Baseline visit

description:
600498.0001A.CEL
whole blood of Interferon treated MS patient, sample 600498.0001A, Interferon Analysis, replication data set


title: MS patient 600498.0001, follow-up year 2 visit

description:
600498.0001C.CEL
whole blood of Interferon treated MS patient, sample 600498.0001C, Interferon Analysis, replication data set


title: MS patient 41790.0001, follow-up year 2 visit

description:
41790.0001C.CEL
whole blood of Interferon treated MS patient, sample 41790.0001C, Interferon Analysis, replication data set


title: MS patient 41497.0001, follow-up year 1 visit [re-analysis]

description:
41497.0001B.CEL
whole blood of untreated MS patient, sample 41497.0001B, MS vs Ctrl Analysis, discovery data set


title: MS patient 41462.0001, Baseline visit [re-analysis]

description:
41462.0001A.CEL
whole blood of untreated MS patient, sample 41462.0001A, MS vs Ctrl Analysis, discovery data set


title: MS patient 600505.0001, Baseline visit

description:
600505.0001A.CEL
whole blood of untreated MS patient, sample 600505.0001A, Interferon Analysis, replication data set

source_name: MS patient_untreated_Baseline


title: MS patient 41689.0001, Baseline visit

description:
41689.0001A.CEL
whole blood of untreated MS patient, sample 41689.0001A, Interferon Analysis, replication data set


title: MS patient 600477.0001, follow-up year 1 visit

description:
600477.0001B.CEL
whole blood of Interferon treated MS patient, sample 600477.0001B, Interferon Analysis, replication data set

value: Interferon - Betaseron


title: MS patient 600477.0001, Baseline visit

description:
600477.0001A.CEL
whole blood of Interferon treated MS patient, sample 600477.0001A, Interferon Analysis, replication data set


title: MS patient 41672.0001, follow-up year 2 visit

description:
41672.0001C.CEL
whole blood of Interferon treated MS patient, sample 41672.0001C, Interferon Analysis, replication data set


title: MS patient 600473.0001, follow-up year 2 visit

description:
600473.0001C.CEL
whole blood of Interferon treated MS patient, sample 600473.0001C, Interferon Analysis, replication data set


title: MS patient 600472.0001, follow-up year 1 visit

description:
600472.0001B.CEL
whole blood of Interferon treated MS patient, sample 600472.0001B, Interferon Analysis, replication data set


title: MS patient 600472.0001, Baseline visit

description:
600472.0001A.CEL
whole blood of Interferon treated MS patient, sample 600472.0001A, Interferon Analysis, replication data set


title: MS patient 600426.0001, follow-up year 2 visit

description:
600426.0001C.CEL
whole blood of Interferon treated MS patient, sample 600426.0001C, Interferon Analysis, replication data set


title: MS patient 41656.0001, follow-up year 2 visit

description:
41656.0001C.CEL
whole blood of untreated MS patient, sample 41656.0001C, Interferon Analysis, replication data set

source_name: MS patient_untreated_follow-up year 2


title: MS patient 600462.0001, Baseline visit

description:
600462.0001A.CEL
whole blood of untreated MS patient, sample 600462.0001A, Interferon Analysis, replication data set


title: MS patient 600473.0001, Baseline visit

description:
600473.0001A.CEL
whole blood of Interferon treated MS patient, sample 600473.0001A, Interferon Analysis, replication data set


title: MS patient 41656.0001, Baseline visit

description:
41656.0001A.CEL
whole blood of untreated MS patient, sample 41656.0001A, Interferon Analysis, replication data set


title: MS patient 41739.0001, follow-up year 1 visit

description:
41739.0001B.CEL
whole blood of untreated MS patient, sample 41739.0001B, Interferon Analysis, replication data set


title: MS patient 41672.0001, follow-up year 1 visit

description:
41672.0001B.CEL
whole blood of Interferon treated MS patient, sample 41672.0001B, Interferon Analysis, replication data set


title: MS patient 600426.0001, Baseline visit

description:
600426.0001A.CEL
whole blood of Interferon treated MS patient, sample 600426.0001A, Interferon Analysis, replication data set


title: MS patient 600426.0001, follow-up year 1 visit

description:
600426.0001B.CEL
whole blood of Interferon treated MS patient, sample 600426.0001B, Interferon Analysis, replication data set


title: MS patient 600445.0001, follow-up year 2 visit

description:
600445.0001C.CEL
whole blood of untreated MS patient, sample 600445.0001C, Interferon Analysis, replication data set


title: MS patient 600473.0001, follow-up year 1 visit

description:
600473.0001B.CEL
whole blood of Interferon treated MS patient, sample 600473.0001B, Interferon Analysis, replication data set


title: MS patient 600462.0001, follow-up year 2 visit

description:
600462.0001C.CEL
whole blood of untreated MS patient, sample 600462.0001C, Interferon Analysis, replication data set


title: MS patient 41739.0001, follow-up year 2 visit

description:
41739.0001C.CEL
whole blood of untreated MS patient, sample 41739.0001C, Interferon Analysis, replication data set


title: MS patient 41739.0001, Baseline visit

description:
41739.0001A.CEL
whole blood of untreated MS patient, sample 41739.0001A, Interferon Analysis, replication data set


title: MS patient 600437.0001, follow-up year 1 visit

description:
600437.0001B.CEL
whole blood of untreated MS patient, sample 600437.0001B, Interferon Analysis, replication data set


title: MS patient 600445.0001, Baseline visit

description:
600445.0001A.CEL
whole blood of untreated MS patient, sample 600445.0001A, Interferon Analysis, replication data set


title: MS patient 600437.0001, Baseline visit

description:
600437.0001A.CEL
whole blood of Interferon treated MS patient, sample 600437.0001A, Interferon Analysis, replication data set


title: MS patient 600462.0001, follow-up year 1 visit

description:
600462.0001B.CEL
whole blood of untreated MS patient, sample 600462.0001B, Interferon Analysis, replication data set


title: MS patient 600445.0001, follow-up year 1 visit

description:
600445.0001B.CEL
whole blood of untreated MS patient, sample 600445.0001B, Interferon Analysis, replication data set


title: MS patient 41648.0001, Baseline visit

description:
41648.0001A.CEL
whole blood of Interferon treated MS patient, sample 41648.0001A, Interferon Analysis, replication data set


title: MS patient 41648.0001, follow-up year 1 visit

description:
41648.0001B.CEL
whole blood of Interferon treated MS patient, sample 41648.0001B, Interferon Analysis, replication data set


title: MS patient 41648.0001, follow-up year 2 visit

description:
41648.0001C.CEL
whole blood of Interferon treated MS patient, sample 41648.0001C, Interferon Analysis, replication data set


title: MS patient 600472.0001, follow-up year 2 visit

description:
600472.0001C.CEL
whole blood of Interferon treated MS patient, sample 600472.0001C, Interferon Analysis, replication data set


title: MS patient 600477.0001, follow-up year 2 visit

description:
600477.0001C.CEL
whole blood of Interferon treated MS patient, sample 600477.0001C, Interferon Analysis, replication data set


title: MS patient 41834.0001, follow-up year 1 visit

description:
41834.0001B.CEL
whole blood of Interferon treated MS patient, sample 41834.0001B, Interferon Analysis, replication data set


title: MS patient 41672.0001, Baseline visit

description:
41672.0001A.CEL
whole blood of Interferon treated MS patient, sample 41672.0001A, Interferon Analysis, replication data set


title: MS patient 41834.0001, Baseline visit

description:
41834.0001A.CEL
whole blood of Interferon treated MS patient, sample 41834.0001A, Interferon Analysis, replication data set


title: MS patient 600388.0001, follow-up year 2 visit

description:
600388.0001C.CEL
whole blood of Interferon treated MS patient, sample 600388.0001C, Interferon Analysis, replication data set


title: MS patient 600388.0001, Baseline visit

description:
600388.0001A.CEL
whole blood of Interferon treated MS patient, sample 600388.0001A, Interferon Analysis, replication data set


title: MS patient 41656.0001, follow-up year 1 visit

description:
41656.0001B.CEL
whole blood of untreated MS patient, sample 41656.0001B, Interferon Analysis, replication data set


title: MS patient 600368.0001, Baseline visit

description:
600368.0001A.CEL
whole blood of Interferon treated MS patient, sample 600368.0001A, Interferon Analysis, replication data set


title: MS patient 600373.0001, Baseline visit

description:
600373.0001A.CEL
whole blood of Interferon treated MS patient, sample 600373.0001A, Interferon Analysis, replication data set


title: MS patient 41163.0001, follow-up year 2 visit

description:
41163.0001C.CEL
whole blood of Interferon treated MS patient, sample 41163.0001C, Interferon Analysis, replication data set


title: MS patient 600347.0001, follow-up year 1 visit

description:
600347.0001B.CEL
whole blood of untreated MS patient, sample 600347.0001B, Interferon Analysis, replication data set


title: MS patient 600349.0001, follow-up year 1 visit

description:
600349.0001B.CEL
whole blood of Interferon treated MS patient, sample 600349.0001B, Interferon Analysis, replication data set


title: MS patient 41607.0001, follow-up year 1 visit

description:
41607.0001B.CEL
whole blood of Interferon treated MS patient, sample 41607.0001B, Interferon Analysis, replication data set


title: MS patient 600362.0001, follow-up year 2 visit

description:
600362.0001C.CEL
whole blood of Interferon treated MS patient, sample 600362.0001C, Interferon Analysis, replication data set


title: MS patient 600349.0001, follow-up year 2 visit

description:
600349.0001C.CEL
whole blood of Interferon treated MS patient, sample 600349.0001C, Interferon Analysis, replication data set


title: MS patient 600347.0001, Baseline visit

description:
600347.0001A.CEL
whole blood of untreated MS patient, sample 600347.0001A, Interferon Analysis, replication data set


title: MS patient 600317.0001, follow-up year 2 visit

description:
600317.0001C.CEL
whole blood of Interferon treated MS patient, sample 600317.0001C, Interferon Analysis, replication data set


title: MS patient 41163.0001, Baseline visit

description:
41163.0001A.CEL
whole blood of Interferon treated MS patient, sample 41163.0001A, Interferon Analysis, replication data set


title: MS patient 600373.0001, follow-up year 2 visit

description:
600373.0001C.CEL
whole blood of Interferon treated MS patient, sample 600373.0001C, Interferon Analysis, replication data set


title: MS patient 600368.0001, follow-up year 1 visit

description:
600368.0001B.CEL
whole blood of Interferon treated MS patient, sample 600368.0001B, Interferon Analysis, replication data set


title: MS patient 41632.0001, follow-up year 2 visit

description:
41632.0001C.CEL
whole blood of untreated MS patient, sample 41632.0001C, Interferon Analysis, replication data set


title: MS patient 41632.0001, follow-up year 1 visit

description:
41632.0001B.CEL
whole blood of untreated MS patient, sample 41632.0001B, Interferon Analysis, replication data set


title: MS patient 41163.0001, follow-up year 1 visit

description:
41163.0001B.CEL
whole blood of Interferon treated MS patient, sample 41163.0001B, Interferon Analysis, replication data set


title: MS patient 600335.0001, follow-up year 1 visit

description:
600335.0001B.CEL
whole blood of untreated MS patient, sample 600335.0001B, Interferon Analysis, replication data set


title: MS patient 600335.0001, follow-up year 2 visit

description:
600335.0001C.CEL
whole blood of untreated MS patient, sample 600335.0001C, Interferon Analysis, replication data set


title: MS patient 600335.0001, Baseline visit

description:
600335.0001A.CEL
whole blood of untreated MS patient, sample 600335.0001A, Interferon Analysis, replication data set


title: MS patient 600292.0001, follow-up year 1 visit

description:
600292.0001B.CEL
whole blood of untreated MS patient, sample 600292.0001B, Interferon Analysis, replication data set


title: MS patient 600292.0001, follow-up year 2 visit

description:
600292.0001C.CEL
whole blood of Interferon treated MS patient, sample 600292.0001C, Interferon Analysis, replication data set


title: MS patient 41632.0001, Baseline visit

description:
41632.0001A.CEL
whole blood of untreated MS patient, sample 41632.0001A, Interferon Analysis, replication data set


title: MS patient 600284.0001, follow-up year 2 visit

description:
600284.0001C.CEL
whole blood of Interferon treated MS patient, sample 600284.0001C, Interferon Analysis, replication data set


title: MS patient 600284.0001, Baseline visit

description:
600284.0001A.CEL
whole blood of Interferon treated MS patient, sample 600284.0001A, Interferon Analysis, replication data set


title: MS patient 41718.0001, follow-up year 2 visit

description:
41718.0001C.CEL
whole blood of Interferon treated MS patient, sample 41718.0001C, Interferon Analysis, replication data set


title: MS patient 41718.0001, follow-up year 1 visit

description:
41718.0001B.CEL
whole blood of Interferon treated MS patient, sample 41718.0001B, Interferon Analysis, replication data set


title: MS patient 600292.0001, Baseline visit

description:
600292.0001A.CEL
whole blood of untreated MS patient, sample 600292.0001A, Interferon Analysis, replication data set


title: MS patient 600281.0001, Baseline visit

description:
600281.0001A.CEL
whole blood of untreated MS patient, sample 600281.0001A, Interferon Analysis, replication data set


title: MS patient 600284.0001, follow-up year 1 visit

description:
600284.0001B.CEL
whole blood of Interferon treated MS patient, sample 600284.0001B, Interferon Analysis, replication data set


title: MS patient 600349.0001, Baseline visit

description:
600349.0001A.CEL
whole blood of Interferon treated MS patient, sample 600349.0001A, Interferon Analysis, replication data set


title: MS patient 600280.0001, follow-up year 1 visit

description:
600280.0001B.CEL
whole blood of Interferon treated MS patient, sample 600280.0001B, Interferon Analysis, replication data set


title: MS patient 600253.0001, follow-up year 1 visit

description:
600253.0001B.CEL
whole blood of Interferon treated MS patient, sample 600253.0001B, Interferon Analysis, replication data set


title: MS patient 600280.0001, follow-up year 2 visit

description:
600280.0001C.CEL
whole blood of Interferon treated MS patient, sample 600280.0001C, Interferon Analysis, replication data set


title: MS patient 41196.0001, follow-up year 2 visit

description:
41196.0001C.CEL
whole blood of Interferon treated MS patient, sample 41196.0001C, Interferon Analysis, replication data set


title: MS patient 600280.0001, Baseline visit

description:
600280.0001A.CEL
whole blood of Interferon treated MS patient, sample 600280.0001A, Interferon Analysis, replication data set


title: MS patient 600257.0001, Baseline visit

description:
600257.0001A.CEL
whole blood of untreated MS patient, sample 600257.0001A, Interferon Analysis, replication data set


title: MS patient 600253.0001, Baseline visit

description:
600253.0001A.CEL
whole blood of Interferon treated MS patient, sample 600253.0001A, Interferon Analysis, replication data set


title: MS patient 600253.0001, follow-up year 2 visit

description:
600253.0001C.CEL
whole blood of Interferon treated MS patient, sample 600253.0001C, Interferon Analysis, replication data set


title: MS patient 41196.0001, follow-up year 1 visit

description:
41196.0001B.CEL
whole blood of Interferon treated MS patient, sample 41196.0001B, Interferon Analysis, replication data set


title: MS patient 600257.0001, follow-up year 2 visit

description:
600257.0001C.CEL
whole blood of untreated MS patient, sample 600257.0001C, Interferon Analysis, replication data set


title: MS patient 600279.0001, follow-up year 2 visit

description:
600279.0001C.CEL
whole blood of untreated MS patient, sample 600279.0001C, Interferon Analysis, replication data set


title: MS patient 600240.0001, follow-up year 1 visit

description:
600240.0001B.CEL
whole blood of Interferon treated MS patient, sample 600240.0001B, Interferon Analysis, replication data set


title: MS patient 600257.0001, follow-up year 1 visit

description:
600257.0001B.CEL
whole blood of untreated MS patient, sample 600257.0001B, Interferon Analysis, replication data set


title: MS patient 600245.0001, follow-up year 1 visit

description:
600245.0001B.CEL
whole blood of untreated MS patient, sample 600245.0001B, Interferon Analysis, replication data set


title: MS patient 41567.0001, follow-up year 2 visit

description:
41567.0001C.CEL
whole blood of Interferon treated MS patient, sample 41567.0001C, Interferon Analysis, replication data set


title: MS patient 600240.0001, Baseline visit

description:
600240.0001A.CEL
whole blood of Interferon treated MS patient, sample 600240.0001A, Interferon Analysis, replication data set


title: MS patient 600245.0001, Baseline visit

description:
600245.0001A.CEL
whole blood of untreated MS patient, sample 600245.0001A, Interferon Analysis, replication data set


title: MS patient 600245.0001, follow-up year 2 visit

description:
600245.0001C.CEL
whole blood of untreated MS patient, sample 600245.0001C, Interferon Analysis, replication data set


title: MS patient 41567.0001, Baseline visit

description:
41567.0001A.CEL
whole blood of untreated MS patient, sample 41567.0001A, Interferon Analysis, replication data set


title: MS patient 600240.0001, follow-up year 2 visit

description:
600240.0001C.CEL
whole blood of Interferon treated MS patient, sample 600240.0001C, Interferon Analysis, replication data set


title: MS patient 41196.0001, Baseline visit

description:
41196.0001A.CEL
whole blood of Interferon treated MS patient, sample 41196.0001A, Interferon Analysis, replication data set


title: MS patient 41567.0001, follow-up year 1 visit

description:
41567.0001B.CEL
whole blood of Interferon treated MS patient, sample 41567.0001B, Interferon Analysis, replication data set


title: MS patient 600230.0001, follow-up year 2 visit

description:
600230.0001C.CEL
whole blood of Interferon treated MS patient, sample 600230.0001C, Interferon Analysis, replication data set


title: MS patient 600230.0001, Baseline visit

description:
600230.0001A.CEL
whole blood of Interferon treated MS patient, sample 600230.0001A, Interferon Analysis, replication data set


title: MS patient 610039.0001, Baseline visit

description:
610039.0001A.CEL
whole blood of Interferon treated MS patient, sample 610039.0001A, Interferon Analysis, replication data set


title: MS patient 600229.0001, follow-up year 2 visit

description:
600229.0001C.CEL
whole blood of untreated MS patient, sample 600229.0001C, Interferon Analysis, replication data set


title: MS patient 610039.0001, follow-up year 1 visit

description:
610039.0001B.CEL
whole blood of untreated MS patient, sample 610039.0001B, Interferon Analysis, replication data set


title: MS patient 41554.0001, follow-up year 2 visit

description:
41554.0001C.CEL
whole blood of Interferon treated MS patient, sample 41554.0001C, Interferon Analysis, replication data set


title: MS patient 41554.0001, follow-up year 1 visit

description:
41554.0001B.CEL
whole blood of Interferon treated MS patient, sample 41554.0001B, Interferon Analysis, replication data set


title: MS patient 600229.0001, follow-up year 1 visit

description:
600229.0001B.CEL
whole blood of untreated MS patient, sample 600229.0001B, Interferon Analysis, replication data set


title: MS patient 41743.0001, Baseline visit

description:
41743.0001A.CEL
whole blood of untreated MS patient, sample 41743.0001A, Interferon Analysis, replication data set


title: MS patient 41743.0001, follow-up year 1 visit

description:
41743.0001B.CEL
whole blood of untreated MS patient, sample 41743.0001B, Interferon Analysis, replication data set


title: MS patient 600203.0001, follow-up year 2 visit

description:
600203.0001C.CEL
whole blood of Interferon treated MS patient, sample 600203.0001C, Interferon Analysis, replication data set


title: MS patient 41743.0001, follow-up year 2 visit

description:
41743.0001C.CEL
whole blood of untreated MS patient, sample 41743.0001C, Interferon Analysis, replication data set


title: MS patient 600188.0001, follow-up year 2 visit

description:
600188.0001C.CEL
whole blood of untreated MS patient, sample 600188.0001C, Interferon Analysis, replication data set


title: MS patient 600203.0001, Baseline visit

description:
600203.0001A.CEL
whole blood of Interferon treated MS patient, sample 600203.0001A, Interferon Analysis, replication data set


title: MS patient 600182.0001, follow-up year 2 visit

description:
600182.0001C.CEL
whole blood of Interferon treated MS patient, sample 600182.0001C, Interferon Analysis, replication data set


title: MS patient 600189.0001, follow-up year 2 visit

description:
600189.0001C.CEL
whole blood of untreated MS patient, sample 600189.0001C, Interferon Analysis, replication data set


title: MS patient 600188.0001, Baseline visit

description:
600188.0001A.CEL
whole blood of untreated MS patient, sample 600188.0001A, Interferon Analysis, replication data set


title: MS patient 600188.0001, follow-up year 1 visit

description:
600188.0001B.CEL
whole blood of untreated MS patient, sample 600188.0001B, Interferon Analysis, replication data set


title: MS patient 600182.0001, follow-up year 1 visit

description:
600182.0001B.CEL
whole blood of Interferon treated MS patient, sample 600182.0001B, Interferon Analysis, replication data set


title: MS patient 600189.0001, follow-up year 1 visit

description:
600189.0001B.CEL
whole blood of untreated MS patient, sample 600189.0001B, Interferon Analysis, replication data set


title: MS patient 41137.0001, Baseline visit

description:
41137.0001A.CEL
whole blood of Interferon treated MS patient, sample 41137.0001A, Interferon Analysis, replication data set


title: MS patient 600183.0001, Baseline visit

description:
600183.0001A.CEL
whole blood of untreated MS patient, sample 600183.0001A, Interferon Analysis, replication data set


title: MS patient 41137.0001, follow-up year 1 visit

description:
41137.0001B.CEL
whole blood of Interferon treated MS patient, sample 41137.0001B, Interferon Analysis, replication data set


title: MS patient 600203.0001, follow-up year 1 visit

description:
600203.0001B.CEL
whole blood of Interferon treated MS patient, sample 600203.0001B, Interferon Analysis, replication data set


title: MS patient 600178.0001, Baseline visit

description:
600178.0001A.CEL
whole blood of Interferon treated MS patient, sample 600178.0001A, Interferon Analysis, replication data set


title: MS patient 600182.0001, Baseline visit

description:
600182.0001A.CEL
whole blood of untreated MS patient, sample 600182.0001A, Interferon Analysis, replication data set


title: MS patient 600178.0001, follow-up year 1 visit

description:
600178.0001B-2.CEL
whole blood of Interferon treated MS patient, sample 600178.0001B-2, Interferon Analysis, replication data set


title: MS patient 41137.0001, follow-up year 2 visit

description:
41137.0001C.CEL
whole blood of Interferon treated MS patient, sample 41137.0001C, Interferon Analysis, replication data set


title: MS patient 600155.0001, Baseline visit

description:
600155.0001A.CEL
whole blood of Interferon treated MS patient, sample 600155.0001A, Interferon Analysis, replication data set


title: MS patient 600159.0001, follow-up year 2 visit

description:
600159.0001C.CEL
whole blood of Interferon treated MS patient, sample 600159.0001C, Interferon Analysis, replication data set


title: MS patient 600178.0001, follow-up year 2 visit

description:
600178.0001C.CEL
whole blood of Interferon treated MS patient, sample 600178.0001C, Interferon Analysis, replication data set